DDInter1340 DDInter1658
Originally approved by the FDA in 1989, omeprazole is a _proton-pump inhibitor_, used to treat gastric acid-related disorders. These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid. This drug was the first clinical useful drug in its class, and its approval was followed by the formulation of many other proton pump inhibitor drugs. Omeprazole is generally effective and well-tolerated, promoting its popular use in children and adults [FDA label].
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Omeprazole {u} (Compound) resembles {v} (Compound) Pantoprazole
Omeprazole {u} (Compound) resembles {v} (Compound) Esomeprazole
Omeprazole {u} (Compound) treats {v} (Disease) Barrett's esophagus
Omeprazole {u} (Compound) binds {v} (Gene) CYP1A2
Omeprazole {u} (Compound) upregulates {v} (Gene) TIPARP
Omeprazole {u} (Compound) palliates {v} (Disease) systemic scleroderma
Omeprazole {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2C19 Inhibitors
Omeprazole {u} (Compound) downregulates {v} (Gene) THAP11
Omeprazole {u} (Compound) causes {v} (Side Effect) Alanine aminotransferase increased
Omeprazole (Compound) resembles Pantoprazole (Compound)
Omeprazole (Compound) resembles Esomeprazole (Compound)
Omeprazole (Compound) treats Barrett's esophagus (Disease)
Omeprazole (Compound) binds CYP1A2 (Gene)
Omeprazole (Compound) upregulates TIPARP (Gene)
Omeprazole (Compound) palliates systemic scleroderma (Disease)
Omeprazole (Compound) is included by Cytochrome P450 2C19 Inhibitors (Pharmacologic Class)
Omeprazole (Compound) downregulates THAP11 (Gene)
Omeprazole (Compound) causes Alanine aminotransferase increased (Side Effect)